Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Capital Employed: 2018-2025

Historic Return on Capital Employed for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Sep 2025 value amounting to -0.41%.

  • Crinetics Pharmaceuticals' Return on Capital Employed fell 6.00% to -0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.41%, marking a year-over-year decrease of 6.00%. This contributed to the annual value of -0.35% for FY2024, which is 15.00% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Return on Capital Employed of -0.41% as of Q3 2025, which was down 21.50% from -0.34% recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Return on Capital Employed's 5-year high stood at -0.28% during Q1 2025, with a 5-year trough of -0.71% in Q2 2023.
  • In the last 3 years, Crinetics Pharmaceuticals' Return on Capital Employed had a median value of -0.35% in 2024 and averaged -0.41%.
  • In the last 5 years, Crinetics Pharmaceuticals' Return on Capital Employed plummeted by 34bps in 2023 and then spiked by 40bps in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Return on Capital Employed (Quarterly) stood at -0.37% in 2021, then decreased by 12bps to -0.49% in 2022, then grew by 12bps to -0.37% in 2023, then increased by 7bps to -0.30% in 2024, then dropped by 6bps to -0.41% in 2025.
  • Its Return on Capital Employed was -0.41% in Q3 2025, compared to -0.34% in Q2 2025 and -0.28% in Q1 2025.